Suppr超能文献

在对1220例由医生改良的开窗、分支型血管腔内修复术治疗复杂腹主动脉瘤和胸腹主动脉瘤进行中期随访时发现,低轮廓腔内移植物与I/III型内漏风险增加相关。

Low-profile endografts are associated with increased risk of type I/III endoleaks at midterm follow-up of 1220 physician-modified fenestrated, branched endovascular repairs for complex abdominal and thoracoabdominal aortic aneurysms.

作者信息

Han Sukgu M, Melo Ryan Gouveia, Beck Adam, Schermerhorn Marc, Kölbel Tilo, Sweet Matthew, Barleban Andrew, Adam Donald, Farber Mark, Mendes Bernardo, Oderich Gustavo, Tsilimparis Nikolaos

机构信息

Keck Medical Center of University of Southern California, Los Angeles, CA.

Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.

出版信息

J Vasc Surg. 2025 Aug 8. doi: 10.1016/j.jvs.2025.08.002.

Abstract

OBJECTIVE

Physician-modified endografts (PMEGs) are widely used for complex abdominal and thoracoabdominal aortic repairs, offering versatility in patient-specific stent graft configurations. Low-profile (LP) endografts improve deliverability and decrease access site complications compared with standard-profile (SP) devices. However, concerns have been raised about the long-term durability of certain LP devices. Although LP devices have been incorporated into PMEGs at many centers, data on their impact on outcomes are limited. Therefore, this study compared outcomes of LP and SP endografts used with PMEGs using an international multicenter database.

METHODS

A retrospective analysis of data on patients who received PMEGs at 19 international centers from 2009 to 2022 was conducted. Patients were grouped by LP or SP aortic endografts used for modification. Baseline patient characteristics, aortic pathologies, modification techniques, and outcomes were compared. Primary outcomes included technical success, 30-day mortality, and type I and III endoleaks. The secondary outcomes were major adverse events, access site complications, all-cause and aneurysm-related mortality, and target vessel instability during follow-up.

RESULTS

Among 1220 patients included (393 LP, 827 SP), the LP group was older and had higher rates of congestive heart failure, any history of smoking, and an American Society of Anesthesiologists risk score of ≥3. LP devices were more commonly used in elective cases; with short neck aneurysms, postdissection aneurysms, and prior endovascular repairs; and during the latter one-half of the study period. Reinforced fenestration was the most common modification in both groups, with directional branches and preloaded components more common in the LP groups. The LP group required fewer access conduits and a lower radiation dose. There was no difference in technical success (92.5 LP vs 94.5% SP; P = .19), mortality (4.1 LP vs 6.8% LP; P = .06), major adverse events (23.1 LP vs 25.7% SP; P = .38), and access-site complications (8.1 LP vs 11.7% SP; P = .06) at 30 days as well as all-cause and aneurysm-related mortality and target vessel instability during follow-up. However, at a median follow-up of 20 months, significantly more type I or III endoleaks (23% LP vs 13% SP; P < .001) were seen in the LP group. Furthermore, the estimated 2-year branch-related endoleaks (type Ic, IIIc) were higher (hazard ratio, 1.65; P = .014) in the LP group.

CONCLUSIONS

The use of LP devices facilitated safe PMEG repair with a lesser need for access conduit. However, the higher rates of type I, type III, and branch-related endoleaks with LP devices raise concerns about their long-term durability; however, more study is required. Based on these data, the use of LP devices for PMEGs should be approached with caution.

摘要

目的

医生改良型腔内移植物(PMEG)广泛用于复杂的腹主动脉和胸腹主动脉修复,在针对患者的支架移植物配置方面具有通用性。与标准外形(SP)装置相比,低外形(LP)腔内移植物提高了输送性并减少了穿刺部位并发症。然而,人们对某些LP装置的长期耐用性提出了担忧。尽管许多中心已将LP装置纳入PMEG,但关于其对治疗结果影响的数据有限。因此,本研究使用国际多中心数据库比较了与PMEG一起使用的LP和SP腔内移植物的治疗结果。

方法

对2009年至2022年在19个国际中心接受PMEG治疗的患者数据进行回顾性分析。患者按用于改良的LP或SP主动脉腔内移植物分组。比较患者的基线特征、主动脉病变、改良技术和治疗结果。主要结局包括技术成功、30天死亡率以及I型和III型内漏。次要结局为主要不良事件、穿刺部位并发症、全因死亡率和动脉瘤相关死亡率,以及随访期间靶血管失稳。

结果

在纳入的1220例患者中(393例LP,827例SP),LP组患者年龄较大,充血性心力衰竭、有吸烟史以及美国麻醉医师协会风险评分≥3的比例更高。LP装置更常用于择期手术;用于短颈动脉瘤、夹层后动脉瘤和既往血管腔内修复;以及在研究期的后半段。强化开窗是两组中最常见的改良方式,定向分支和预装组件在LP组中更常见。LP组所需的穿刺导管更少,辐射剂量更低。30天时技术成功(LP组为92.5%,SP组为94.5%;P = 0.19)、死亡率(LP组为4.1%,SP组为6.8%;P = 0.06)、主要不良事件(LP组为23.1%,SP组为25.7%;P = 0.38)和穿刺部位并发症(LP组为8.1%,SP组为11.7%;P = 0.06)以及随访期间的全因死亡率、动脉瘤相关死亡率和靶血管失稳方面均无差异。然而,在中位随访20个月时,LP组中I型或III型内漏明显更多(LP组为23%,SP组为13%;P < 0.001)。此外,LP组估计的2年分支相关内漏(Ic型、IIIc型)更高(风险比,1.65;P = 0.014)。

结论

LP装置的使用有助于安全的PMEG修复,且对穿刺导管的需求较少。然而,LP装置的I型、III型和分支相关内漏发生率较高,引发了对其长期耐用性的担忧;不过,还需要更多研究。基于这些数据,PMEG使用LP装置时应谨慎。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验